Polaryx Therapeutics (PLYX)
Develops PLX-200 and other candidates for rare pediatric lysosomal storage disorders.
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs. Polaryx continues to advance clinical trial start-up activities in collaboration with its contract research organization (CRO) and remains focused on initiating SOTERIA in the fourth quarter of 2026.
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that it has closed a private investment in public equity (“PIPE”) financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026.
Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia. “The NTSAD Annual Family Conference is an important opportunity to connect directly with the families and advocates at the heart of the rare disease community,” said Alex Yang, J.D.
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond honoree for Excellence in Pediatric Care
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces that members of the executive team will be participating in the 25th Annual Needham Virtual Healthcare Conference.
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces its participation in two upcoming events supporting the Krabbe disease community. These events reflect Polaryx's ongoing commitment to advancing research and strengthening engagement with patients, caregivers, and clinicians.
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers.
What's Going On With Polaryx Therapeutics Stock Wednesday?
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it has selected a leading contract research organization (CRO) for SOTERIA, a phase 2, open-label, single-arm trial designed to evaluate the safety, tolerability, and clinical activity of Polaryx's lead candidate, PLX-200, across four different LSDs. “Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic,” said Lisa Bollinger, M.D.
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that the late-breaking presentation of new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, was given on February 6, 2026 in San Diego, Calif. Key Findings and Scientific Perspective At the Contemporary Forum, Late-breaking Science and the Rapid Fire Competition, Shrijay Vijayan, Ph.D.
Polaryx Therapeutics Welcomes New Members of the Board of Directors
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announces the appointments of Mitchel Berger, M.D., Francis A.
Polaryx Therapeutics Seeks Direct Listing For Shareholders
Polaryx Therapeutics is pursuing a direct listing with no proceeds to the company and no new institutional investors involved. PLYX is a clinical-stage biopharma targeting lysosomal storage disorders, but has no safety or efficacy data and is thinly capitalized. The lysosomal storage disorder market is growing, but PLYX faces intense competition from established players and lacks major pharma partnerships.